Abivax dazzled investors and analysts with positive data from a pair of Phase III induction trials assessing obefazimod in adults with moderately to severely active ulcerative colitis. The results ...

YCT-529, a novel non-hormonal male contraceptive, demonstrates safety and tolerability in early trials, offering a potential ...

YourChoice Therapeutics, a biotech company based in California, has reported promising safety data from an early-stage ...

Having recently scored approval for Nucala in chronic obstructive pulmonary disease (COPD), GSK has now signed a major ...